Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KuicK Research | PRODUCT CODE: 1733556

Cover Image

PUBLISHER: KuicK Research | PRODUCT CODE: 1733556

Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030

PUBLISHED:
PAGES: 1200 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 6000
PDF (Multi-User License)
USD 10000

Add to Cart

Global Multispecific Antibodies Market, Drug Sales, Dosage, Price & Clinical Trials Insight 2030 Report Highlights:

  • Global Multispecific Antibodies Market Opportunity By 2030: > USD 50 Billion
  • Global Multispecific Antibodies Market Sales In 2024: > USD 12 Billion
  • Number Of Approved Multispecific Antibodies: 18
  • Global & Regional Trends Insight
  • Approved Antibodies Global, Regional, Annual & Quarterly Sales Insight
  • Approved Antibodies Dosage & Pricing Insight
  • Comprehensive Insight On All Antibodies In Clinical Trials By Company, Country, Indication & Phase
  • Number Of Multispecific Antibodies: In Clinical Trials: > 700

Research Methodology

At Kuick Research, we begin by outlining the foundation of our research methodology, which is driven by an integrated approach that combines multiple data dimensions. In our work, we ensure that the report captures market estimation, regional analysis, and a carefully constructed competitive landscape. We take pride in the detailed inclusion of key components such as the assessment of available information, clinical trial data, and the nuances of dosing and pricing. Every piece of data is purposefully gathered and validated to ensure that our findings are as robust as possible, reflecting the multifaceted nature of the market landscape.

This report on the global multispecific antibodies market is the result of comprehensive primary and secondary research, encompassing 18 approved drugs, alongside in-depth analysis of their pricing, dosing, and sales data. Market size, marketed drugs regional sales analysis and recent trends are also included in the report. To ensure the accuracy and reliability of our analysis on multispecific antibodies pricing and market performance, we leveraged an extensive array of sources, including company reports, exchange filings, annual and quarterly reports, and official press releases.

  • Over 10000 distinct web links were reviewed for comprehensive clinical trial information on more than 700 multispecific antibodies.
  • For annual, quarterly, global and regional sales analysis, SEC documents, company reports, declarations, press releases were analyzed.
  • Open source and proprietary sources were accessed to validate FDA designated orphan drug indications & priority status.
  • Multiple drug specific website and various news, company press releases were examined to gather detailed drug pricing and dosage information

Multispecific antibodies market globally has been one of the most energetic and fast growing sectors in the biopharmaceutical business as a result of therapeutic breakthroughs and growing acceptance of their ability to treat complicated pathologies by targeting multiple pathways simultaneously. As of May 2025, 18 multispecific antibodies have gained regulatory approval globally, all of which are bispecific constructs, a monumental milestone in the history of targeted therapeutics. This expanding portfolio boasts trailblazing drugs like Blincyto, the first bispecific antibody to gain approval, and Hemlibra, which was the first bispecific antibody to be approved for a non-cancer indication. The latest entrant to this therapeutic pipeline is Regeneron's Lynozyfic, which received marketing approval in April 2025 for the treatment of multiple myeloma, with evidence of ongoing momentum in the segment.

The range of approved multispecific antibodies mirrors the flexibility of this therapeutic modality across various disease indications and patient bases. Rybrevant is another key breakthrough as the first bispecific antibody for a solid tumor, whereas China based Akeso's Cadonilimab is especially noteworthy for being solely approved bispecific antibody intended to target two immune checkpoints at once and becoming the first China developed bispecific antibody to gain regulatory approval. This regional variation in development emphasizes the world nature of innovation in this sector, with input from both mature pharmaceutical markets and developing biotechnology centers.

The regulatory environment is still changing at a rapid pace, with further approvals expected in the near future. The FDA is also evaluating marketing applications for Odronextamab and Linvoseltamab, both of which have already received approval in the EU for follicular lymphoma and diffuse large B-cell lymphoma, and multiple myeloma, respectively. Such transatlantic regulatory advancements reflect the growing acceptability and trust in multispecific antibody technologies by global regulatory bodies.

Market performance has been extremely strong, with global multispecific antibodies market sales in 2024 amounting to over US$ 12.6 Billion, followed by first quarter 2025 sales of over US$ 3.46 Billion. The US is the largest contributor to these sales, highlighting the maturity and acceptance of the market in this prime geography. Roche's mature products, Hemlibra and Vabysmo, lead the market share, with over half of total sales, emphasizing the value of first mover benefit and effective market entry strategies in this competitive market.

The pipeline for development is an even more daunting picture, with more than 900 multispecific antibodies already in various stages of development. Oncology is leading this pipeline, both due to the traditional priority of multispecific antibody development and due to the large unmet medical needs in cancer treatment. However, pipeline diversity is not confined to oncology alone with promising candidates being identified in autoimmune and inflammatory diseases and neurological disorders as well, indicating an expanding therapeutic horizon that has the potential to dramatically expand market opportunities.

Major industry players behind this innovation are well established pharma giants like Amgen, AstraZeneca, Genentech, and Regeneron, as well as new biotech firms like ABL Bio, Harbour BioMed, Innovent Biologics, Merus, and Zymeworks. This combination of well established and new players provides a vibrant competitive landscape that ensures ongoing innovation and technological progress.

Strategic alliances continue to influence the development of the market, such as in the April 2025 alliance of Boehringer Ingelheim and Cue Biopharma for the development of CUE-501, a bispecific candidate that attacks pathogenic B cells via virus-specific memory T cells. The alliance, involving a US$ 12 Million upfront payment and possible milestone payments of up to US$ 345 Million, illustrates the high financial investment that companies are undertaking to drive multispecific antibody technologies, specifically in autoimmune indications where existing treatments are still inadequate.

Regulatory encouragement of innovation continues to be robust, with the FDA's April 2025 fast track designation of ISB 2001, an Ichnos Glenmark Innovation investigational trispecific T-cell engager for relapsed or refractory multiple myeloma, reflecting ongoing regulatory enthusiasm for moving multispecific antibody technologies forward that treat important unmet medical needs. As a result of these ongoing innovations, the global multispecific antibody market is expected to grow rapidly and is on track to become one of the most important segments within the pharmaceutical industry.

Table of Contents

1. Introduction to Next Generation Multispecific Antibodies

2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook

  • 2.1 Current Market Overview
  • 2.2 Future Commercialization Opportunity
  • 2.3 Collaborations, License Agreements, Investments & Acquisitions
  • 2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company

3. Next Generation Multispecific Antibody Clinical Trends by Indication

  • 3.1 Cancer
  • 3.2 Hematological Disorders
  • 3.3 Microbial Infections
  • 3.4 Autoimmune & Inflammatory Disorders
  • 3.5 Ocular Diseases

4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region

  • 4.1 US
  • 4.2 EU
  • 4.3 China
  • 4.4 UK
  • 4.5 Japan
  • 4.6 Australia
  • 4.7 South Korea
  • 4.8 Canada

5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight

  • 5.1 Overview
  • 5.2 Clinical Overview, Pricing & Dosage Insight

6. Approved Multispecific Antibodies - Sales Insight (2020 - Q1'2025)

7. Global Multispecific Antibodies Clinical Trials Overview

8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Phase-I
  • 8.4 Phase-I/II
  • 8.5 Phase-II
  • 8.6 Phase-II/III
  • 8.7 Phase-III
  • 8.8 Preregistration
  • 8.9 Registered

9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Phase I
  • 10.4 Phase I/II
  • 10.5 Phase II/III

11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

  • 11.1 Preclinical
  • 11.2 Phase I
  • 11.3 Phase I/II
  • 11.4 Phase II

12. Competitive Landscape

  • 12.1 AbbVie
  • 12.2 ABL Bio
  • 12.3 Abzyme Therapeutics
  • 12.4 Affimed Therapeutics
  • 12.5 Akeso Biopharma
  • 12.6 Alligator Bioscience
  • 12.7 Amgen
  • 12.8 Antibody Therapeutics
  • 12.9 APITBIO
  • 12.10 Astellas Pharma
  • 12.11 AstraZeneca
  • 12.12 Aptevo Therapeutics
  • 12.13 BioAtla
  • 12.14 Biocytogen Pharmaceuticals
  • 12.15 Biosion
  • 12.16 EpimAb Biotherapeutics
  • 12.17 FutureGen Biopharmaceutical
  • 12.18 Genentech
  • 12.19 Genmab
  • 12.20 Genor Biopharma
  • 12.21 Gensun Biopharma
  • 12.22 Harbour BioMed
  • 12.23 IGM Biosciences
  • 12.24 I-MAB Biopharma
  • 12.25 ImmuneOnco Biopharma
  • 12.26 ImmunoPrecise Antibodies
  • 12.27 Innate Pharma
  • 12.28 Innovent Biologics
  • 12.29 Invenra
  • 12.30 Johnson & Johnson
  • 12.31 Kenjockety Biotechnology
  • 12.32 LaNova Medicines Limited
  • 12.33 Light Chain Bioscience
  • 12.34 Linton Pharm
  • 12.35 Lyvgen Biopharma
  • 12.36 MacroGenics
  • 12.37 Merck
  • 12.38 Merus
  • 12.39 ModeX Therapeutics (OPKO Health)
  • 12.40 Molecular Partners
  • 12.41 NovaRock Biotherapeutics
  • 12.42 Numab
  • 12.43 OPKO Health
  • 12.44 Pfizer
  • 12.45 Regeneron Pharmaceuticals
  • 12.46 Revitope
  • 12.47 Roche
  • 12.48 Sanofi
  • 12.49 Sichuan Baili Pharmaceutical
  • 12.50 SystImmune
  • 12.51 Virtuoso Therapeutics
  • 12.52 Xencor
  • 12.53 Y-Biologics
  • 12.54 Zhejiang Shimai Pharmaceutical
  • 12.55 Zymeworks

List of Figures

  • Figure 2-1: Global - Multispecific Antibodies Sales (US$ Million), 2020-2025
  • Figure 2-2: Global - Market Sales by Multispecific Antibodies (US$ Million), Q1'2025
  • Figure 2-3: Global -Market Sales by Multispecific Antibodies (%), Q1'2025
  • Figure 2-4: Global - Market Sales by Multispecific Antibodies (US$ Million), 2024
  • Figure 2-5: Global -Market Sales by Multispecific Antibodies (%),2024
  • Figure 2-6: Global - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4'2024
  • Figure 2-7: US - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4'2024
  • Figure 2-8: ROW - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4'2024
  • Figure 2-9: Global - Multispecific Antibody Market Opportunity Assessment (US$ Billion), 2025 - 2030
  • Figure 2-10: Grabody I Platform - Mechanism of Action 1
  • Figure 2-11: Grabody I Platform - Mechanism of Action 2
  • Figure 2-12: Abz2 Bispecific Platform
  • Figure 2-13: Abz2 Bispecifics - Benefits
  • Figure 2-14: Neo-X-Prime Bispecific Mechanism
  • Figure 2-15: BiTE - Structure
  • Figure 2-16: BiTE Molecule
  • Figure 2-17: ADAPTIR Bispecific Structure
  • Figure 2-18: ADAPTIR-FLEX
  • Figure 2-19: BioAtla CABs - Features
  • Figure 2-20: BioAtla CABs - Benefits
  • Figure 2-21: FIT-Ig - Proprietary Bispecific Platform
  • Figure 2-22: 3-Step DuoBody Production Process
  • Figure 2-23: DuoHexaBody Molecules - Schematic
  • Figure 2-24: BEAT Platform - Multispecific Antibodies
  • Figure 2-25: IMBiologic Bispecific Antibodies - Strategy
  • Figure 2-26: IMBiologic Bispecific Antibodies - Mechanism of Action
  • Figure 2-27: ANKET(R) Platform - Innate Pharma
  • Figure 2-28: B-Body Bispecific Antibody - Structre
  • Figure 2-29: iTAb - Patented Structure
  • Figure 2-30: iTAb - Mechanism of Action
  • Figure 2-31: xLinkBsAb - Structure
  • Figure 2-32: Multiclonics - Distinctive Characteristics
  • Figure 2-33: Biclonics - Format
  • Figure 2-34: Merus - Triclonics Platform
  • Figure 2-35: STEALTH - ModeX Therapeutics
  • Figure 2-36: MSTAR - ModeX Therapeutics
  • Figure 2-37: MSTAR - Features
  • Figure 2-38: DARPin Platform - Molecular Partners
  • Figure 2-39: Novel HBICE
  • Figure 2-40: HBICE - Mechanism of Action 1
  • Figure 2-41: HBICE - Mechanism of Action 2
  • Figure 2-42: Numab Therapeutics - Technology
  • Figure 2-43: Phanes Therapeutics - PACbody Platform
  • Figure 2-44: Phanes Therapeutics - SPECpair Platform
  • Figure 2-45: Phanes Therapeutics - ATACCbody
  • Figure 2-46: Purple Biotech - Tribody Antibody Platform
  • Figure 2-47: PrecisionGATE Bispecific Antibody - Structure
  • Figure 2-48: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
  • Figure 2-49: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
  • Figure 2-50: Synimmune - Proprietary Bispecific Antibody Format
  • Figure 2-51: ALiCE - Characteristics
  • Figure 2-52: ALiCE - Schematic Diagram & Mechanism of Action
  • Figure 2-53: BiClone format
  • Figure 2-54: Zyngenia Technology Approach
  • Figure 3-1: Odronextamab (ELM-1) Phase I (NCT02290951) Study - Initiation & Completion Year
  • Figure 3-2: Odronextamab (ELM-1) Phase II (NCT03888105) Study - Initiation & Completion Year
  • Figure 3-3: Linvoseltamab (LINKER-MM1) Phase I/II (NCT03761108) Study - Initiation & Completion Year
  • Figure 3-4: PIT565 Phase I (NCT05397496) Study - Initiation & Completion Year
  • Figure 3-5: JNJ-79635322 Phase I (NCT05652335) Study - Initiation & Completion Year
  • Figure 3-6: GNC-038 Phase I/II (NCT05192486) Study - Initiation & Completion Year
  • Figure 3-7: GNC-038 Phase I/II (NCT05485753) Study - Initiation & Completion Year
  • Figure 3-8: IPH6501 Phase I/II (NCT06088654) Study - Initiation & Completion Year
  • Figure 3-9: AFM13 Phase I/II (NCT04074746) Study - Initiation & Completion Year
  • Figure 3-10: NM32-2668 Phase I (NCT06299163) Study - Initiation & Completion Year
  • Figure 3-11: GB263T Phase I/II (NCT05332574) Study - Initiation & Completion Year
  • Figure 3-12: GNC-039 Phase I (NCT04794972) Study - Initiation & Completion Year
  • Figure 3-13: Emicizumab (AHAEmi) Phase II (NCT05345197) Study - Initiation & Completion Year
  • Figure 3-14: Emicizumab Phase II/III (NCT06155955) Study - Initiation & Completion Year
  • Figure 3-15: Emicizumab (BCDI-XII) Phase I (NCT05500807) Study - Initiation & Completion Year
  • Figure 3-16: HMB-001 Phase I/II (NCT06211634) Study - Initiation & Completion Year
  • Figure 3-17: YBSW015 Early Phase I (NCT05369754) Study - Initiation & Completion Year
  • Figure 3-18: CLN-978 (CLN-978-SL-101) Phase I (NCT06613360) Study - Initiation & Completion Year
  • Figure 3-19: Vabysmo - Approval Year by Indication
  • Figure 3-20: Faricimab (MAGIC) Phase II (NCT05681884) Study - Initiation & Completion Year
  • Figure 3-21: Restoret (EYE103) - Tetravalent, Trispecific Antibody Binding Sites
  • Figure 3-22: Restoret (BRUNELLO) Phase II/III (NCT06571045) Study - Initiation & Completion Year
  • Figure 3-23: Restoret (BAROLO) Phase II/III (NCT06957080) Study - Initiation & Completion Year
  • Figure 4-1: US - Approved Multispecific Antibodies
  • Figure 4-2: EU - Approved Multispecific Antibodies
  • Figure 4-3: Japan - Approved Multispecific Antibodies
  • Figure 4-4: Chugai Pharmaceutical - Multispecific Antibody Clinical Pipeline
  • Figure 4-5: SAIL66 Phase I (NCT05735366) Study - Initiation & Completion Year
  • Figure 4-6: ONO-4685 (ONO-4685-05) Phase I (NCT06547528) Study - Initiation & Completion Year
  • Figure 4-7: ABL Bio - Bispecific Antibody Pipeline
  • Figure 4-8: ZW171 (ZWI-ZW171-101) Phase I (NCT06523803) Study - Initiation & Completion Year
  • Figure 5-1: Blincyto - Approval Year by Region
  • Figure 5-2: Blincyto - Patent Filing & Expiration Year
  • Figure 5-3: Blincyto - Treatment Regimen Cycles (Weeks)
  • Figure 5-4: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
  • Figure 5-5: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
  • Figure 5-6: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
  • Figure 5-7: Hemlibra - Approval Years by Region
  • Figure 5-8: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection of Different Volumes (US$), May'2025
  • Figure 5-9: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection of Different Volumes (US$), May'2025
  • Figure 5-10: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
  • Figure 5-11: Rybrevant - Price per Unit & Supply of Intravenous Solution (US$), May'2025
  • Figure 5-12: Rybrevant - Recommended Dose per Cycle by Body Weight (mg)
  • Figure 5-13: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
  • Figure 5-14: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
  • Figure 5-15: Vabysmo - First Approval Year by Region
  • Figure 5-16: Vabysmo - Price per Unit & Supply of Intravitreal Solution (US$), May'2025
  • Figure 5-17: Lunsumio - Approval Years by Region
  • Figure 5-18: US - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), May'2025
  • Figure 5-19: EU - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), May'2025
  • Figure 5-20: Tecvayli - Approval Years by Region
  • Figure 5-21: Tecvayli - Patent Acceptance & Expiration Years
  • Figure 5-22: US - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), May'2025
  • Figure 5-23: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), May'2025
  • Figure 5-24: Columvi - Approval Year by Region
  • Figure 5-25: US - Price per Unit & Supply of Columvi Intravenous Solution (US$), May'2025
  • Figure 5-26: EU - Price per Unit & Supply of Columvi Intravenous Solution (US$), May'2025
  • Figure 5-27: Epkinly - Approval Year by Region
  • Figure 5-28: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), May'2025
  • Figure 5-29: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), May'2025
  • Figure 5-30: Talvey - Approval Year by Region
  • Figure 5-31: Talquetamab - FDA & EMA Designation Year
  • Figure 5-32: Talvey - Patent Acceptance & Expiration Year
  • Figure 5-33: US - Price per Unit & Supply of Talvey Intravenous Solution (US$), May'2025
  • Figure 5-34: EU - Price per Unit & Supply of Talvey Intravenous Solution (US$), February'2024
  • Figure 5-35: Elrexfio - Approval Years by Region
  • Figure 5-36: Elranatamab - FDA & EMA Designation Year
  • Figure 5-37: US - Price per Unit & Supply of Elrexfio Subcutaneous Solution (US$), May'2025
  • Figure 5-38: Imdelltra - Approval Years by Region
  • Figure 5-39: Imdelltra - Price per Unit & Supply of Intravenous Powder (US$), May'2025
  • Figure 5-40: US - Price Per Unit & Supply Of Ziihera (US$), May'2025
  • Figure 5-41: Zenocutuzumab - Active Patents
  • Figure 6-1: Global - Annual Blincyto Sales (US$ Million), 2020-2025
  • Figure 6-2: Regional - Blincyto Sales (US$ Million), Q1'2025
  • Figure 6-3: Regional - Blincyto Sales Quarterly (%), Q1'2025
  • Figure 6-4: Blincyto - Sales By Region (US$ Million), 2024
  • Figure 6-5: Blincyto - Sales By Region (%), 2024
  • Figure 6-6: US - Blincyto Sales ((US$ Million), 2020-2025
  • Figure 6-7: US - Blincyto Sales Quarterly (US$ Million), 2024
  • Figure 6-8: ROW - Blincyto Sales (US$ Million), 2020-2025
  • Figure 6-9: ROW - Blincyto Sales Quarterly (US$ Million), 2024
  • Figure 6-10: Global - Annual Hemlibra Sales (US$ Million), 2020-2024
  • Figure 6-11: Regional - US v/s ROW Sales (US$ Million), Q1'2025
  • Figure 6-12: Global - Hemlibra Sales by Region (US$ Million), Q1'2025
  • Figure 6-13: Global - Hemlibra Sales by Region (%), Q1'2025
  • Figure 6-14: Regional - US v/s ROW Sales (US$ Million), 2024
  • Figure 6-15: Global - Hemlibra Sales by Region (US$ Million), 2024
  • Figure 6-16: Global - Hemlibra Sales by Region (%),'2024
  • Figure 6-17: Global - Hemlibra Sales Quarterly (US$ Million), 2024
  • Figure 6-18: US - Annual Hemlibra Sales (US$ Million), 2020-2025
  • Figure 6-19: US - Hemlibra Sales Quarterly (US$ Million), 2024
  • Figure 6-20: Europe - Annual Hemlibra Sales (US$ Million), 2020-2025
  • Figure 6-21: Europe - Hemlibra Sales Quarterly (US$ Million), 2024
  • Figure 6-22: Japan - Annual Hemlibra Sales (US$ Million), 2020-2025
  • Figure 6-23: Japan - Hemlibra Sales Quarterly (US$ Million), 2024
  • Figure 6-24: ROW - Hemlibra Sales (US$ Million), 2020-2025
  • Figure 6-25: ROW - Hemlibra Sales Quarterly (US$ Million), 2024
  • Figure 6-26: Global - Annual Vabysmo Sales (US$ Million), 2022-2025
  • Figure 6-27: Global - Vabysmo US v/s ROW Sales (US$ Million), Q1'2025
  • Figure 6-28: Global - Vabysmo Sales by Region (US$ Million), Q1'2025
  • Figure 6-29: Global - Vabysmo Annual Sales by Region (%), Q1'2025
  • Figure 6-30: Global - Vabysmo US v/s ROW Sales (US$ Million), 2024
  • Figure 6-31: Global - Vabysmo Sales by Region (US$ Million), 2024
  • Figure 6-32: Global - Vabysmo Annual Sales by Region (%), 2024
  • Figure 6-33: Global - Vabysmo Sales Quarterly (US$ Million), 2024
  • Figure 6-34: US - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 6-35: US - Vabysmo Sales Quarterly (US$ Million), 2024
  • Figure 6-36: Europe - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 6-37: Europe - Vabysmo Sales Quarterly (US$ Million), 2024
  • Figure 6-38: Japan - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 6-39: Japan - Vabysmo Sales Quarterly (US$ Million), 2024
  • Figure 6-40: ROW - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 6-41: ROW - Vabysmo Sales Quarterly (US$ Million), 2024
  • Figure 6-42: Global - Annual Lunsumio Sales (US$ Million), 2022-2025
  • Figure 6-43: Global - Lunsumio US v/s ROW Sales (US$ Million), Q1'2025
  • Figure 6-44: Global - Lunsumio Sales by Region (US$ Million), Q1'2025
  • Figure 6-45: Global - Lunsumio Annual Sales by Region (%), Q1'2025
  • Figure 6-46: Global - Lunsumio US v/s ROW Sales (US$ Million), 2024
  • Figure 6-47: Global - Lunsumio Sales by Region (US$ Million), 2024
  • Figure 6-48: Global - Lunsumio Annual Sales by Region (%), 2024
  • Figure 6-49: Global - Lunsumio Sales Quarterly (US$ Million), 2024
  • Figure 6-50: US - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 6-51: US - Lunsumio Sales Quarterly (US$ Million), 2024
  • Figure 6-52: Europe - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 6-53: Europe - Lunsumio Sales Quarterly (US$ Million), 2024
  • Figure 6-54: ROW - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 6-55: ROW - Lunsumio Sales Quarterly (US$ Million), 2024
  • Figure 6-56: Global - Tecvayli Sales (US$ Million), 2022-2025
  • Figure 6-57: Regional - Tecvayli Sales US$ Million), Q1'2025
  • Figure 6-58: Regional - Tecvayli Sales (%), Q1'2025
  • Figure 6-59: Global - Tecvayli Sales Quarterly (US$ Million), 2024
  • Figure 6-60: Regional - Tecvayli Sales (US$ Million), 2024
  • Figure 6-61: Regional - Tecvayli Sales (%), 2024
  • Figure 6-62: US - Tecvayli Sales (US$ Million), 2022-2025
  • Figure 6-63: US - Tecvayli Sales Quaterly (US$ Million), 2024
  • Figure 6-64: ROW - Tecvayli Sales (US$ Million), 2022-2025
  • Figure 6-65: ROW - Tecvayli Sales Quarterly (US$ Million), 2024
  • Figure 6-66: Global - Annual Columvi Sales (US$ Million), 2023-2025
  • Figure 6-67: Regional - US v/s ROW Sales (US$ Million), Q1'2025
  • Figure 6-68: Global - Columvi Sales by Region (US$ Million), Q1'2025
  • Figure 6-69: Global - Columvi Sales by Region (%), Q1'2025
  • Figure 6-70: Regional - US v/s ROW Sales (US$ Million), 2024
  • Figure 6-71: Global - Columvi Sales by Region (US$ Million), 2024
  • Figure 6-72: Global - Columvi Sales by Region (%),'2024
  • Figure 6-73: Global - Columvi Sales Quarterly (US$ Million), 2024
  • Figure 6-74: US - Annual Columvi Sales (US$ Million), 2023-2025
  • Figure 6-75: US - Columvi Sales Quarterly (US$ Million), 2024
  • Figure 6-76: Europe - Annual Columvi Sales (US$ Million), 2023-2025
  • Figure 6-77: Europe - Columvi Sales Quarterly (US$ Million), 2024
  • Figure 6-78: ROW - Columvi Sales (US$ Million), 2023-2025
  • Figure 6-79: ROW - Columvi Sales Quarterly (US$ Million), 2024
  • Figure 6-80: Global - Annual Epkinly Sales (US$ Million), 2023-2025
  • Figure 6-81: Global - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
  • Figure 6-82: US - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
  • Figure 6-83: ROW - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
  • Figure 6-84: Annual - Cadonilimab Sales (US$ Million), 2022-2024
  • Figure 6-85: Global - Annual Talvey Sales (US$ Million), 2025
  • Figure 6-86: Regional - Talvey Sales (US$ Million), Q1'2025
  • Figure 6-87: Regional - Talvey Sales Quarterly (%), Q1'2025
  • Figure 6-88: Global - Elrexfio Sales (US$ Million), 2023-2025
  • Figure 6-89: Global - Annual Elrexfio Sales (US$ Million), 2025
  • Figure 6-90: Regional - Elrexfio Sales (US$ Million), Q1'2025
  • Figure 6-91: Regional - Elrexfio Sales Quarterly (%), Q1'2025
  • Figure 6-92: US - Elrexfio Sales (US$ Million), 2023-2025
  • Figure 6-93: ROW - Elrexfio Sales (US$ Million), 2023-2025
  • Figure 6-94: Global - Imdelltra Sales (US$ Million), 2024-2025
  • Figure 6-95: Regional - Imdelltra Sales (US$ Million), Q1'2025
  • Figure 6-96: Regional - Imdelltra Sales Quarterly (%), Q1'2025
  • Figure 6-97: Global - Imdelltra Sales Quarterly (US$ Million), 2024
  • Figure 6-98: US - Imdelltra Sales (US$ Million), 2024-2025
  • Figure 6-99: US - Imdelltra Sales (US$ Million), 2024-2025
  • Figure 6-100: ROW - Imdelltra Sales (US$ Million), 2024-2025
  • Figure 6-101: Global - Ordspono Sales (US$ Million), 2022-2024
  • Figure 6-102: Global - Ordspono Sales Quarterly (US$ Million), 2024
  • Figure 6-103: Global - Ziihera Sales (US$ Million), 2024
  • Figure 7-1: Global - Multispecific Antibodies Clinical Trials by Phase (Numbers), 2025 till 2030
  • Figure 7-2: Global - Bispecific Antibodies Clinical Trials by Phase (Numbers), 2025 till 2030
  • Figure 7-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2025 till 2030
  • Figure 7-4: Global - Trispecific Antibodies Clinical Trials by Phase, 2025 till 2030

List of Tables

  • Table 2-1: Estimated Total Cancer Cases, 2022 & 2040
  • Table 2-2: Multispecific Antibodies Under Regulatory Review
  • Table 3-1: Hematological Cancers - Approved Multispecific Antibodies
  • Table 3-2: Hematological Malignancies - Estimated Total Cancer Cases, 2022 & 2040
  • Table 3-3: Solid Cancers - Approved Multispecific Antibodies
  • Table 3-4: Solid Cancers - Estimated Total Cancer Cases, 2022 & 2040
  • Table 4-1: US - Multispecific Antibodies in Clinical Trials
  • Table 4-2: EU - Multispecific Antibodies in Clinical Trials
  • Table 4-3: UK - Multispecific Antibodies in Clinical Trials
  • Table 4-4: Japan - Multispecific Antibodies in Clinical Trials
  • Table 4-5: Australia - Multispecific Antibodies in Clinical Trials
  • Table 4-6: South Korea - Multispecific Antibodies in Clinical Trials
  • Table 4-7: Canada - Multispecific Antibodies in Clinical Trials
  • Table 5-1: Approved Multispecific Antibodies
  • Table 5-2: Blincyto - Active Patents
  • Table 5-3: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
  • Table 5-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
  • Table 5-5: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
  • Table 5-6: Rybrevant - Premedication
  • Table 5-7: Rybrevant - Dose Reductions for Adverse Reactions
  • Table 5-8: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
  • Table 5-9: Lunsumio - Recommended Treatment Cycles
  • Table 5-10: Lunsumio - Recommended Premedications
  • Table 5-11: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
  • Table 5-12: Tecvayli - Dosing Schedule
  • Table 5-13: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
  • Table 5-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)
  • Table 5-15: Columvi - Premedications to be Administered
  • Table 5-16: Columvi - Recommendations for Management of Cytokine Release Syndrome
  • Table 5-17: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
  • Table 5-18: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 5-19: Epkinly - Dosage Schedule
  • Table 5-20: Epkinly - Recommendations for Management of Cytokine Release Syndrome
  • Table 5-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 5-22: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 5-23: Talvey - Weekly Dosing Schedule
  • Table 5-24: Talvey - Biweekly Dosing Schedule
  • Table 5-25: Talvey - Recommendations for Management of CRS
  • Table 5-26: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 5-27: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
  • Table 5-28: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 5-29: Elrexfio - Dosing Schedule
  • Table 5-30: Elrexfio - Recommendations for Management of CRS
  • Table 5-31: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions
  • Table 5-32: Kaitani - Recommended Dose modifications
  • Table 5-33: Imdelltra - Recommended Concomitant Medications for Administration for Cycle 1
  • Table 5-34: Imdelltra - Recommended Dosage and Schedule
  • Table 5-35: Imdelltra - Recommendations for Restarting Therapy After Dosage Delay
  • Table 5-36: Imdelltra - Guidelines for Grading & Dosage Modification & Management of Cytokine Release Syndrome
  • Table 5-37: Imdelltra - Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome
  • Table 5-38: Ordspono - Recommended dose
  • Table 5-39: Ordspono - Premedications & post-medications for patients with r/r FL or r/r DLBCL
  • Table 5-40: Ziihera - Dosage Modifications For Adverse Reactions
  • Table 5-41: Bizengri - Premedications Prior To Infusions
  • Table 5-42: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions
  • Table 5-43: Lynozyfic - Recommended Posology
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!